Fauci’s Promotional Hype Catapults Gilead’s Remdesivir – Alliance for Human Research Protection

Fauci’s Promotional Hype Catapults Gilead’s Remdesivir – Alliance for Human Research Protection

Unlike other drugs being tested against the new coronavirus, remdesivir hasn’t received official approval for any use in normal conditions anywhere in the world against any illness.
On April 29, 2020, Chinese remdesivir study was published in The Lancet, a premier scientific journal. The trial was stopped before completion because of serious adverse events in 16 (12%) of the patients compared to four (5%) of patients in the placebo group. On the same day, Gilead issued a press release announcing that it “was aware of positive data emerging from the National Institute of Allergy and Infectious Disease (NIAID) study.”

Based on the “positive data” from the NIAID study, the Food and Drug Administration approved emergency use of remdesivir against COVID-19 on May 1.

Dr Anthony Fauci Promoting remdesivir _White House

The same day, Dr. Anthony Fauci, who heads the President’s Coronavirus Task Force, and heads the NIAID, since 1984, has a vested interest in remdesivir. He sponsored the clinical trial whose detailed results have not been peer-reviewed. What’s more, HE declared the tenuous results to be “highly significant,” and pronounced remdesivir to be the new “standard of care.”
[See YouTube Video of his statement from the White House]

Dr. Fauci made the promotional pronouncement while sitting on a couch in the White House, without providing a detailed news release; without a briefing at a medical meeting or in a scientific journal – as is the norm and practice, to allow scientists and researchers to review the data.

via AHRP Fauci’s Promotional Hype Catapults Gilead’s Remdesivir – Alliance for Human Research Protection

All hype, within a nothing burger.

One thought on “Fauci’s Promotional Hype Catapults Gilead’s Remdesivir – Alliance for Human Research Protection

Comments are closed.